Introduction
Molecular biology offers new opportunities for clinical medicine. A promising clinical application of molecular biology is the identification of mRNA expression patterns in diseased organs. These mRNA expression patterns may provide information regarding diagnosis, prognosis and responsiveness to treatment. The development of technologies such as microarray analysis and real-time PCR enables the study of gene expression networks in renal biopsies. This fact, in combination with the usage of laser-capture microdissection, enables gene expression analysis in a nephron segment-specific way. We will elaborate on the potential applications of mRNA assessment in clinical nephrology. Progress in the optimization of protocols for acquiring adequate renal tissue and intact RNA will be discussed.
Perspectives of mRNA assessment in clinical practice
The question of why it is useful to analyse levels of mRNA in renal biopsies must be answered. Firstly, mRNA quantitation could be used as a diagnostic tool. In renal pathology, it is sometimes difficult to formulate a diagnosis on the sole basis of clinical and histological findings. Molecular analysis of the tissue with RNA quantitation may help improve diagnostic accuracy. Secondly, mRNA levels could be used as prognostic tools. Studies in animal models [1] [2] [3] and, more recently, in biopsy specimens from patients [4] [5] [6] have shown that alterations in mRNA levels for extracellular matrix (ECM) molecules and ECM-regulating molecules predict the extent of scarring in later phases of the disease. Furthermore, recent studies in kidney transplantation [7] [8] [9] and in native kidney diseases [10, 11] show that mRNA levels of transcripts identified by microarray analysis may serve as a complement to histological findings for the formulation of the patient's prognosis. Thirdly, mRNA assessment may be used as a tool to predict the response of the patient to therapy. Support for this concept has been provided by Sarwal et al. They showed that a relatively high expression of CD20, a marker for B cells, during acute rejection is associated with resistance to anti-rejection therapy [8] . In another report, Fas ligand mRNA levels predicted unresponsiveness to anti-rejection therapy [12] . Fourthly, mRNA assessment may be used as a tool to monitor the extent of a therapy's negative side effects over time. For example, mRNA levels of TGF-b and collagens I and III have been used to compare the fibrogenic effects of different calcineurin inhibitors on kidney grafts [6, 13, 14] . Usage of sequential protocol biopsies in mRNA assessment makes it possible to accurately monitor changes over time in the activity rate of profibrotic pathways under the influence of maintenance immunosuppressive medications. Fifthly, investigation of gene expression levels in renal tissue samples will elucidate the pathogenesis of kidney diseases.
Overall, we envision that the use of molecular markers in addition to conventional parameters including morphology will lead to a more accurate prognosis and will therefore enable the application of more individualized therapeutic regimens. The response of patients to anti-rejection medication and maintenance therapy may be predicted more accurately on the basis of molecular markers.
Messenger RNA assessment in clinical biopsies for the applications mentioned above requires optimal protocols for tissue acquirement and RNA extraction. In the next chapter, we will discuss the progress that Toward an optimal protocol for the acquisition of intact RNA from renal tissue During the course of renal disease, different compartments of the kidney are affected in different ways. Molecular mechanisms that pertain to the development of glomerular lesions may differ from those that pertain to the development of tubulointerstitial lesions. Therefore, separate analysis of glomerular tissue from renal biopsies at the mRNA level provides useful information, which complements the information gathered through mRNA analysis of whole cortical renal tissue alone. In some renal disease entities including minimal change disease, morphological alterations are generally observed only in the glomeruli. Messenger RNA levels determined in glomerular tissue, rather than in the whole renal cortex, would in that case more directly and adequately reflect the molecular composition of the glomeruli.
Glomeruli were initially separated from the tubulointerstitium through manual microdissection of fresh renal biopsies [15] [16] [17] [18] [19] 21] . Only when a biopsy yielded an amount of tissue that was sufficient for diagnostic purposes, a small piece of cortex (usually 1-2 mm in length) was cut off for microdissection. The cortical tissue was disrupted with the aid of two small needles, and at that point the glomeruli became visible under a stereomicroscope as separate structures among the tubulointerstitial tissue ( Figure 1A ). The glomeruli were removed from the surrounding tissue with a pipette and washed to remove tissue debris. Glomeruli were then stored at À80 C until RNA extraction. Several methods can be used to extract RNA from small amounts of glomerular tissue. With mild soap solutions such as Nonidet P-40 and Triton X-100 glomeruli are permeabilized, and subsequently cDNA can be synthesized in situ. This method has often been applied to freshly obtained, microdissected glomeruli [15, 17, 19] . For several years, an RNA-extraction method which makes use of Trizol Õ (Invitrogen) has been available. This method is based on phenol/ chloroform-mediated extraction of RNA. More recently, silica-gel spin columns have been developed (e.g. RNeasy mini columns, Qiagen), which can be used in combination with the stringency of guanidineisothiocyanate lysis. Silica-gel based spin columns offer a rapid method to isolate intact RNA from renal biopsy tissue, derived from either the whole cortex or the glomeruli.
One of the principal problems with RNA isolation is that mRNA molecules are sensitive to degradation by endonucleases and exonucleases. Thawing of frozen archival biopsy material leads to RNA degradation [19, 20] . The RNA-preserving compound RNAlater has been proven to conserve the integrity of the RNA in whole renal cortical tissue that is stored at 4 C or lower temperatures for a prolonged time period.
It will also minimize RNA degradation in frozen tissue during thawing [20, 21] . However, treatment of the whole renal cortical tissue with RNAlater is detrimental for glomerular morphology and complicates manual glomerular microdissection [20] . For several years, laser-capture microdissection has been used to obtain specific structures, such as glomeruli, from frozen [22, 23] and formalin-fixed [24] renal biopsies. With this technique, glomeruli can be selected from a renal tissue slide, captured by a laser beam ( Figure 1B) , and catapulted into a reaction tube for mRNA assessment; RNA-preserving compounds are not necessary. Laser-capture microdissection has made archival material available for research purposes. Novel data -obtained through real-time PCR of a household gene on the corresponding cDNA -show that yields of intact RNA from laser-captured glomeruli of frozen renal biopsies are significantly higher than those from manually microdissected glomeruli of fresh renal biopsies (Figure 2) .
The combination of laser-capture microdissection and novel RNA-amplification protocols with a 1000-fold linear amplification efficiency [25] generates nephron segment specific gene profiles in patient material. Recently, gene expression profiling has been performed on individual glomeruli obtained from biopsies with lupus nephritis [26] . These glomeruli had been obtained with laser-capture microdissection. These experiments have provided insight into the extent of interglomerular molecular variations within one patient and into variations in the glomerular expression profile between different patients with a similar renal disease entity. Additionally, nanotechnology-based biochips will definitely gain importance as tools for studying molecular mechanisms at the single cell level [27] .
Conclusion
Measurement of mRNA transcripts may be a sensitive and efficient means to predict outcome in kidney transplantation and native kidney diseases. Messenger RNA assessment may be instrumental in predicting the patient's response to therapy and in monitoring potential long-term side effects of maintenance therapy. Any of these applications in clinical practice requires optimized protocols for extraction of intact RNA from renal biopsy specimens. Research in recent years has generated such protocols. Laser-capture microdissection enables analysis of gene expression in specific renal tissue compartments of archival biopsy tissue. The combination of molecular biological applications, including laser-capture microdissection and differential gene expression analysis, renders a powerful instrument to investigate the mechanisms and pathogenesis of renal disease.
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